BDTX
Black Diamond Therapeutics, Inc.Company Information
- Company Name
- Black Diamond Therapeutics, Inc.
- CIK
- CIK0001701541
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BDTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- BDTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-10-17
- Last sale
- 2025-03-19
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 6,005,892
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 23,204,053
- Shares outstanding
- 57,233,413
- Ownership
- 40.54%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 24.58%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 30 | 21 | 31 | 30 | 98 | 36 | 23 | 33 | 25 | 56 | 58 | ||||||
| Available For Sale Securities Debt Securities Current | 91 | 88 | 108 | 105 | 113 | 54 | 62 | 89 | 90 | 90 | 75 | 86 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 5 | 4 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | ||||||
| Assets Current | 115 | 123 | 132 | 139 | 147 | 156 | 101 | 116 | 127 | 119 | 134 | 147 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 8 | 9 | 9 | 17 | 17 | 18 | 19 | 20 | 21 | 21 | 22 | 23 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Assets | 125 | 133 | 143 | 158 | 166 | 176 | 123 | 138 | 150 | 143 | 159 | 172 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 3 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 2 | 1 | ||||||
| Accrued Liabilities Current | 14 | 12 | 15 | 15 | 16 | 14 | 17 | 19 | 18 | 16 | 17 | 14 | ||||||
| Liabilities Current | 16 | 15 | 16 | 16 | 17 | 17 | 21 | 21 | 18 | 17 | 20 | 15 | ||||||
| Operating Lease Liability Noncurrent | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 21 | 22 | 23 | ||||||
| Liabilities | 29 | 29 | 31 | 32 | 34 | 35 | 39 | 40 | 39 | 38 | 42 | 38 | ||||||
| Commitments And Contingencies | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 580 | 578 | 577 | 576 | 574 | 572 | 570 | 568 | 567 | 540 | 534 | 533 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -484 | -474 | -465 | -450 | -441 | -431 | -487 | -471 | -456 | -436 | -417 | -398 | ||||||
| Stockholders Equity | 96 | 104 | 112 | 126 | 133 | 142 | 83 | 97 | 111 | 104 | 117 | 134 | ||||||
| Liabilities And Stockholders Equity | 125 | 133 | 143 | 158 | 166 | 176 | 123 | 138 | 150 | 143 | 159 | 172 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 56 | 53 | 52 | 52 | ||||||
| Shares Outstanding | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 56 | 53 | 52 | 52 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBlack Diamond Therapeutics, Inc. (BDTX) — SEC Financial Statements & Analysis
Black Diamond Therapeutics, Inc. (BDTX) is a biological products, (no diagnostic substances) company. Black Diamond Therapeutics, Inc. trades on Nasdaq as: BDTX. Black Diamond Therapeutics, Inc. (BDTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Black Diamond Therapeutics, Inc. carries a market cap of $106.13M, a P/E ratio of -2.49x, a P/B ratio of 1.10x, a P/S ratio of 1.97x, an enterprise value of $86.94M, and an EV/EBITDA multiple of -1.68x. On profitability, it posts an operating margin of 17.89%, a net margin of 31.95%, a Return on Equity (ROE) of -37.21%, a Return on Assets (ROA) of -29.21%, and a Return on Invested Capital (ROIC) of -57.64%. Per share, it reports EPS of $-0.74, diluted EPS of $-0.74, free cash flow per share of $-0.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -394.72% year-over-year, and EPS growth of -391.83% year-over-year. On the balance sheet, it maintains a current ratio of 7.28x, a quick ratio of 6.98x, working capital of $99.55M, a debt-to-equity ratio of 0.30x, a debt ratio of 0.23, free cash flow of $-32.84M (TTM), and net debt of $-19.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $106.13M
- P/E TTM
- -2.49x
- EPS TTM
- $-0.74
- P/B TTM
- 1.10x
- ROE TTM
- -37.21%
- ROA TTM
- -29.21%
- Debt To Equity
- 0.30x
- Free Cash Flow TTM
- $-32.84M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Black Diamond Therapeutics, Inc. in?
Black Diamond Therapeutics, Inc. (BDTX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does BDTX trade on?
Black Diamond Therapeutics, Inc. (BDTX) trades on the Nasdaq.
When was Black Diamond Therapeutics, Inc. (BDTX)'s most recent SEC filing?
Black Diamond Therapeutics, Inc. (BDTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is BDTX's market cap?
Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $106.13M as of 2026-06-30.
What is BDTX's EPS (earnings per share)?
Black Diamond Therapeutics, Inc. (BDTX)'s trailing twelve month EPS is $-0.74 as of 2026-06-30.
What is BDTX's ROE (return on equity)?
Black Diamond Therapeutics, Inc. (BDTX)'s trailing twelve month Return on Equity (ROE) is -37.21% as of 2026-06-30.
What is BDTX's ROA (return on assets)?
Black Diamond Therapeutics, Inc. (BDTX)'s trailing twelve month Return on Assets (ROA) is -29.21% as of 2026-06-30.
What is BDTX's ROIC (return on invested capital)?
Black Diamond Therapeutics, Inc. (BDTX)'s trailing twelve month Return on Invested Capital (ROIC) is -57.64% as of 2026-06-30.
What is BDTX's EV/EBITDA?
Black Diamond Therapeutics, Inc. (BDTX)'s trailing twelve month EV/EBITDA is -1.68x as of 2026-06-30.